Valuation: Mangalam Drugs & Organics Limited

Market Cap 527M 5.49M 4.76M 4.5M 4.07M 7.64M 7.7M 53.69M 20.66M 267M 20.63M 20.18M 852M P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 1.65B 17.17M 14.88M 14.07M 12.74M 23.9M 24.08M 168M 64.58M 835M 64.51M 63.08M 2.66B EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
08-17 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
08-12 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
05-14 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
04-17 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
04-16 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
03-26 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
03-17 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
03-17 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
03-17 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
03-17 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
02-06 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
02-06 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day-4.41%
1 week+1.10%
Current month+1.01%
1 month+15.16%
3 months+7.98%
6 months+5.11%
Current year+16.54%
1 week 31.71
Extreme 31.71
38.25
1 month 26.14
Extreme 26.14
38.25
Current year 25.7
Extreme 25.7
54.4
1 year 22.8
Extreme 22.8
77.6
3 years 22.8
Extreme 22.8
144.99
5 years 22.8
Extreme 22.8
173
10 years 20.65
Extreme 20.65
225.7
Manager TitleAgeSince
Chief Executive Officer 72 29/09/2011
Director of Finance/CFO - 05/02/2026
Compliance Officer 27 31/03/2026
Director TitleAgeSince
Chairman 72 01/02/2010
Director/Board Member 75 04/02/2015
Director/Board Member 38 27/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.88%+1.10% - - 5.49M
+0.66%-0.83%+14.83%+61.15% 45.9B
-4.55%-6.60%+28.67%+95.78% 38.7B
-0.22%-2.67%+6.07%+70.55% 11.43B
+0.30%-0.60%-13.09%+9.22% 11.38B
-0.95%0.00%+19.82%+146.45% 9.09B
+0.80%+0.64%+24.85%+37.61% 7.3B
+0.69%-1.93%+14.98%+180.44% 6.98B
-1.00%-0.98%+33.68%-20.38% 7.13B
-2.15%-4.76%-44.26%+4.59% 4.89B
Average -1.06%-2.24%+9.51%+65.04% 15.86B
Weighted average by Cap. -1.08%-2.68%+15.41%+71.20%

Financials

2025 2026
Net sales 3.18B 33.11M 28.68M 27.12M 24.55M 46.08M 46.42M 324M 124M 1.61B 124M 122M 5.14B 2.32B 24.2M 20.96M 19.82M 17.94M 33.68M 33.93M 237M 91M 1.18B 90.9M 88.88M 3.75B
Net income 67.21M 701K 607K 574K 520K 975K 982K 6.85M 2.63M 34.08M 2.63M 2.57M 109M -444M -4.63M -4.01M -3.79M -3.43M -6.44M -6.49M -45.24M -17.41M -225M -17.39M -17M -718M
Net Debt 936M 9.76M 8.46M 8M 7.24M 13.59M 13.69M 95.42M 36.71M 475M 36.67M 35.86M 1.51B 1.12B 11.68M 10.12M 9.57M 8.66M 16.26M 16.38M 114M 43.93M 568M 43.88M 42.9M 1.81B
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
16/09/26 32.24 -3.88% 41,578
15/09/26 ₹33.54 -8.01% 109,928
11/09/26 ₹36.46 +4.53% 385,169
10/09/26 ₹34.88 +10.00% 284,790
09/09/26 ₹31.71 +8.11% 64,156
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!